The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Open accessAbstract
Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and tumor complexity and heterogeneity necessitate customized medicine or targeted therapy. It is critical to identify potential cancer therapeutic targets. Aberrant activation of the PI3K/AKT/mTOR pathway has a significant role in carcinogenesis. This review summarized oncogenic PI3K/Akt/mTOR pathway alterations in cancer and various cancer hallmarks associated with the PI3K/AKT/mTOR pathway, such as cell proliferation, autophagy, apoptosis, angiogenesis, epithelial-to-mesenchymal transition (EMT), and chemoresistance. Importantly, this review provided recent advances in PI3K/AKT/mTOR inhibitor research. Overall, an in-depth understanding of the association between the PI3K/AKT/mTOR pathway and tumorigenesis and the development of therapies targeting the PI3K/AKT/mTOR pathway will help make clinical decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 5×
“PTEN mutations occurred in 9% (888/10336) of patients in the MSK-IMPACT Clinical Sequencing Cohort,whilePTENwasaltered inonly5%(534/10194)ofpatients in China Pan-cancer Cohort (OrigiMed2020) (20, 22).”
BackgroundInfluentialApoptosis in cancer: from pathogenesis to treatment
Wong, R. S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Guidelines and definitions for research on epithelial-mesenchymal transition
Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., Campbell, K., Cano, A., Casanova, J., Christofori, G., et al. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0237-9 · Cited by 2,226
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137 · cited 2×
“The PI3K/AKT/mTOR pathway is crucial for cell motility, growth, survival, and metabolism in cancer (14, 15).”
BackgroundTumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
Self-citationPI3K/AKT/mTOR Pathway in Angiogenesis
Karar, J., & Maity, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00051 · Cited by 1,461
Nishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.213 · Cited by 1,434
TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
Hao, Y., Baker, D., & ten Dijke, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112767 · Cited by 1,142
Integrative clinical genomics of metastatic cancer
Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature · doi:10.1038/nature23306 · Cited by 863
Autophagy as a target for anticancer therapy
Janku, F., McConkey, D. J., Hong, D. S., & Kurzrock, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.71 · Cited by 803
Oncogenic PI3K deregulates transcription and translation
Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Bolton, K. L., Ptashkin, R. N., Gao, T., Braunstein, L., Devlin, S. M., Kelly, D., Patel, M., Berthon, A., Syed, A., Yabe, M., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00710-0 · Cited by 751
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626 · cited 2×
“The most prevalent alterations of MTOR in malignant tumors are E1799K, S2215F, and amplification (29).”
BackgroundBrown, J. R., Byrd, J. C., Coutre, S. E., Benson, D. M., Flinn, I. W., Wagner-Johnston, N. D., Spurgeon, S. E., Kahl, B. S., Bello, C., Webb, H. K., et al. (2014) · Blood · doi:10.1182/blood-2013-11-535047 · Cited by 590
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 576
Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
Foster, K. G., & Fingar, D. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.094003 · Cited by 534
The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review
Rascio, F., Spadaccino, F., Rocchetti, M. T., Castellano, G., Stallone, G., Netti, G. S., & Ranieri, E. (2021) · Cancers · doi:10.3390/cancers13163949 · Cited by 497
mTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
mTORC1 and mTORC2 in cancer and the tumor microenvironment
Kim, L. C., Cook, R. S., & Chen, J. (2017) · Oncogene · doi:10.1038/onc.2016.363 · Cited by 444
The Epithelial-to-Mesenchymal Transition in Cancer
Roche, J. (2018) · Cancers · doi:10.3390/cancers10020052 · Cited by 435
Juric, D., Rodon, J., Tabernero, J., Janku, F., Burris, H. A., Schellens, J. H. M., Middleton, M. R., Berlin, J., Schuler, M., Gil-Martin, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7107 · Cited by 431
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4648 · Cited by 395
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00368 · Cited by 391
Di Leo, A., Johnston, S., Lee, K. S., Ciruelos, E., Lønning, P. E., Janni, W., O'Regan, R., Mouret-Reynier, M.-A., Kalev, D., Egle, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30688-5 · Cited by 381
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Martínez-Sáez, O., Chic, N., Pascual, T., Adamo, B., Vidal, M., González-Farré, B., Sanfeliu, E., Schettini, F., Conte, B., Brasó-Maristany, F., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01284-9 · Cited by 380
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Flinn, I. W., Hillmen, P., Montillo, M., Nagy, Z., Illés, Á., Etienne, G., Delgado, J., Kuss, B. J., Tam, C. S., Gasztonyi, Z., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850461 · Cited by 341
Systematic Functional Annotation of Somatic Mutations in Cancer
Ng, P. K.-S., Li, J., Jeong, K. J., Shao, S., Chen, H., Tsang, Y. H., Sengupta, S., Wang, Z., Bhavana, V. H., Tran, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.021 · Cited by 335
Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., Sandhu, S., Massard, C., Matsubara, N., Alekseev, B., Parnis, F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00580-8 · Cited by 335
Chen, H.-T., Liu, H., Mao, M.-J., Tan, Y., Mo, X.-Q., Meng, X.-J., Cao, M.-T., Zhong, C.-Y., Liu, Y., Shan, H., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1030-2 · Cited by 333
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 316
Lamouille, S., Connolly, E., Smyth, J. W., Akhurst, R. J., & Derynck, R. (2012) · Journal of Cell Science · doi:10.1242/jcs.095299 · Cited by 311
Molecular Genetics of Clear-Cell Renal Cell Carcinoma
Brugarolas, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2003 · Cited by 306
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073464 · Cited by 281
Unraveling the Role of Angiogenesis in Cancer Ecosystems
Zuazo-Gaztelu, I., & Casanovas, O. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00248 · Cited by 275
Flinn, I. W., Miller, C. B., Ardeshna, K. M., Tetreault, S., Assouline, S. E., Mayer, J., Merli, M., Lunin, S. D., Pettitt, A. R., Nagy, Z., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00915 · Cited by 264
Molecular regulation of autophagy machinery by mTOR‐dependent and ‐independent pathways
Al‐Bari, M. A. A., & Xu, P. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14305 · Cited by 261
Karimi Roshan, M., Soltani, A., Soleimani, A., Rezaie Kahkhaie, K., Afshari, A. R., & Soukhtanloo, M. (2019) · Biochimie · doi:10.1016/j.biochi.2019.08.003 · Cited by 254
Deng, J., Bai, X., Feng, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2019) · BMC Cancer · doi:10.1186/s12885-019-5824-9 · Cited by 242
Targeting Akt in cancer for precision therapy
Hua, H., Zhang, H., Chen, J., Wang, J., Liu, J., & Jiang, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01137-8 · Cited by 241
Yoshida, G. J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0436-9 · Cited by 238
Jones, R. H., Casbard, A., Carucci, M., Cox, C., Butler, R., Alchami, F., Madden, T.-A., Bale, C., Bezecny, P., Joffe, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30817-4 · Cited by 229
Iksen, Pothongsrisit, S., & Pongrakhananon, V. (2021) · Molecules · doi:10.3390/molecules26134100 · Cited by 224
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
Li, H., Prever, L., Hirsch, E., & Gulluni, F. (2021) · Cancers · doi:10.3390/cancers13143517 · Cited by 224
Soulières, D., Faivre, S., Mesía, R., Remenár, É., Li, S.-H., Karpenko, A., Dechaphunkul, A., Ochsenreither, S., Kiss, L. A., Lin, J.-C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30064-5 · Cited by 219
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
Martorana, F., Motta, G., Pavone, G., Motta, L., Stella, S., Vitale, S. R., Manzella, L., & Vigneri, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.662232 · Cited by 214
Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials
Harsha, C., Banik, K., Ang, H. L., Girisa, S., Vikkurthi, R., Parama, D., Rana, V., Shabnam, B., Khatoon, E., Kumar, A. P., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093285 · Cited by 212
Pungsrinont, T., Kallenbach, J., & Baniahmad, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011088 · Cited by 210
Gremke, N., Polo, P., Dort, A., Schneikert, J., Elmshäuser, S., Brehm, C., Klingmüller, U., Schmitt, A., Reinhardt, H. C., Timofeev, O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18504-7 · Cited by 187
Alexa, M., Hasenburg, A., & Battista, M. J. (2021) · Cancers · doi:10.3390/cancers13061478 · Cited by 180
Saura, C., Roda, D., Roselló, S., Oliveira, M., Macarulla, T., Pérez-Fidalgo, J. A., Morales-Barrera, R., Sanchis-García, J. M., Musib, L., Budha, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0512 · Cited by 172
Ma, J., Benítez, J. A., Li, J., Miki, S., de Albuquerque, C. P., Galatro, T. F. D. A., Orellana, L., Zanca, C., Reed, R., Boyer, A. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.020 · Cited by 171
Hong, D. S., Bowles, D. W., Falchook, G. S., Messersmith, W. A., George, G. C., O'Bryant, C. L., Vo, A. C. H., Klucher, K., Herbst, R. S., Eckhardt, S. G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0714 · Cited by 169
Wen, P. Y., Touat, M., Alexander, B. M., Mellinghoff, I. K., Ramkissoon, S., McCluskey, C. S., Pelton, K., Haidar, S., Basu, S. S., Gaffey, S. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01207 · Cited by 169
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations
Dogruluk, T., Tsang, Y. H., Espitia, M., Chen, F., Chen, T., Chong, Z., Appadurai, V., Dogruluk, A., Eterovic, A. K., Bonnen, P. E., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1654 · Cited by 168
PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
Fusco, N., Sajjadi, E., Venetis, K., Gaudioso, G., Lopez, G., Corti, C., Guerini Rocco, E., Criscitiello, C., Malapelle, U., & Invernizzi, M. (2020) · Genes · doi:10.3390/genes11070719 · Cited by 166
Neddylation of PTEN regulates its nuclear import and promotes tumor development
Xie, P., Peng, Z., Chen, Y., Li, H., Du, M., Tan, Y., Zhang, X., Lu, Z., Cui, C.-P., Liu, C. H., et al. (2021) · Cell Research · doi:10.1038/s41422-020-00443-z · Cited by 164
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Fowler, N. H., Samaniego, F., Jurczak, W., Ghosh, N., Derenzini, E., Reeves, J. A., Knopińska-Posłuszny, W., Cheah, C. Y., Phillips, T., Lech-Maranda, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03433 · Cited by 161
Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers
Parikh, C., Janakiraman, V., Wu, W., Foo, C. K., Kljavin, N. M., Chaudhuri, S., Stawiski, E. W., Lee, B., Lin, J. M., Li, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204384109 · Cited by 160
Nowosad, A., Jeannot, P., Callot, C., Creff, J., Perchey, R. T., Joffre, C., Codogno, P., Manenti, S., & Besson, A. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0554-4 · Cited by 152
Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma
Motzer, R. J., Hudes, G. R., Curti, B. D., McDermott, D. F., Escudier, B. J., Négrier, S., Duclos, B., Moore, L., O’Toole, T. E., Boni, J. P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5916 · Cited by 138
Beaver, J. A., Gustin, J. P., Yi, K. H., Rajpurohit, A., Thomas, M. C., Gilbert, S. F., Rosen, D. M., Park, B. H., & Lauring, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0884 · Cited by 130
Wise-Draper, T. M., Moorthy, G., Salkeni, M. A., Karim, N. A., Thomas, H. E., Mercer, C. A., Beg, M. S., O’Gara, S., Olowokure, O. O., Fathallah, H., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0482-9 · Cited by 126
Phase II study of PX-866 in recurrent glioblastoma
Pitz, M. W., Eisenhauer, E. A., MacNeil, M. V., Thiessen, B. A., Easaw, J. C., Macdonald, D. R., Eisenstat, D. D., Kakumanu, A. S., Salim, M., Chalchal, H. I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou365 · Cited by 121
Chien, A. J., Tripathy, D., Albain, K. S., Symmans, W. F., Rugo, H. S., Melisko, M., Wallace, A. M., Schwab, R. B., Helsten, T. L., Forero, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01027 · Cited by 115
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor
Kalinsky, K. M., Hong, F., McCourt, C. K., Sachdev, J. C., Mitchell, E. P., Zwiebel, J. A., Doyle, L. A., McShane, L. M., Li, S., Gray, R. J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6741 · Cited by 102
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
Hillmann, P., & Fabbro, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225792 · Cited by 97
Kong, Y., Si, L., Li, Y., Wu, X., Xu, X., Dai, J., Tang, H., Ma, M., Chi, Z., Sheng, X., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1110 · Cited by 95
Rudolph, M., Anzeneder, T., Schulz, A., Beckmann, G., Byrne, A. T., Jeffers, M., Peña, C. E., Politz, O., Köchert, K., Vonk, R., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2626-1 · Cited by 95
He, K., Zheng, X., Li, M., Zhang, L., & Yu, J. (2015) · Oncogene · doi:10.1038/onc.2015.79 · Cited by 94
Khorasani, A. B. S., Pourbagheri‐Sigaroodi, A., Pirsalehi, A., Safaroghli‐Azar, A., Zali, M. R., & Bashash, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173983 · Cited by 94
Makker, V., Recio, F. O., Ma, L., Matulonis, U. A., Lauchle, J., Parmar, H. R., Gilbert, H., Ware, J. A., Zhu, R., Lu, S., et al. (2016) · Cancer · doi:10.1002/cncr.30286 · Cited by 93
Self-citationCrosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer
Evangelisti, C., Chiarini, F., Paganelli, F., Marmiroli, S., & Martelli, A. M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118635 · Cited by 93
Wu, Q., Ma, J., Wei, J., Meng, W., Wang, Y., & Shi, M. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12728 · Cited by 93
Self-citationShen, C., Oswald, D. J., Phelps, D. A., Çam, H., Pelloski, C. E., Pang, Q., & Houghton, P. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4282 · Cited by 92
Duan, Y., Haybaeck, J., & Yang, Z. (2020) · Cancers · doi:10.3390/cancers12102972 · Cited by 92
Massard, C., Chi, K. N., Castellano, D., Bono, J. S. D., Gravis, G., Dirix, L. Y., Machiels, J., Mita, A. C., Mellado, B., Turri, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.024 · Cited by 91
Schmid, P., Zaiss, M. R., Harper-Wynne, C. L., Ferreira, M., Dubey, S., Chan, S. Y. T., Makris, A., Nemsadze, G., Brunt, A. M., Küemmel, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2526 · Cited by 91
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
Lee, B. J., Boyer, J. A., Burnett, G. L., Thottumkara, A. P., Tibrewal, N., Wilson, S. L., Hsieh, T., Marquez, A., Lorenzana, E. G., Evans, J., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00813-7 · Cited by 90
Crabb, S. J., Griffiths, G. O., Marwood, E., Dunkley, D., Downs, N., Martin, K., Light, M., Northey, J., Wilding, S. A., Whitehead, A. L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01576 · Cited by 88
SoxF Transcription Factors Are Positive Feedback Regulators of VEGF Signaling
Kim, K., Kim, I., Yang, J. M., Lee, E., Koh, B. I., Song, S., Park, J., Lee, S., Choi, C., Kim, J. W., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308483 · Cited by 79
Mangé, A., Coyaud, É., Desmetz, C., Laurent, E. M. N., Béganton, B., Coopman, P. J., Raught, B., & Solassol, J. (2019) · Theranostics · doi:10.7150/thno.35561 · Cited by 78
Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis
Chen, Y., Huang, L., Dong, Y., Tao, C., Zhang, R., Shao, H., & Shen, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.573599 · Cited by 65
Gonzalez-Angulo, A. M., Chen, H., Karuturi, M. S., Chávez‐MacGregor, M., Tsavachidis, S., Meric‐Bernstam, F., Do, K.-A., Hortobágyi, G. N., Thompson, P. A., Mills, G. B., et al. (2012) · Cancer · doi:10.1002/cncr.27608 · Cited by 58
Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity*
Murugan, A. K., Alzahrani, A. S., & Xing, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399485 · Cited by 47
Role of Akt isoforms in neuronal insulin signaling and resistance
Sharma, M., & Dey, C. S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03993-6 · Cited by 47
Fan, Y., Sun, T., Shao, Z., Zhang, Q., Ouyang, Q., Tong, Z., Wang, S., Luo, Y., Teng, Y., Wang, X., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3428 · Cited by 43
Wipperman, M. F., Montrose, D. C., Gotto, A. M., & Hajjar, D. P. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.11.013 · Cited by 40
Ji, L., Wu, M., & Li, Z. (2018) · Molecules · doi:10.3390/molecules23082047 · Cited by 37
Colombo, I., Genta, S., Martorana, F., Guidi, M., Frattini, M., Samartzis, E. P., Brandt, S., Gaggetta, S., Moser, L., Pascale, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1402 · Cited by 36
Implications of Akt2/Twist crosstalk on breast cancer metastatic outcome
Pereira, L. P., Horta, S., Mateus, R., & Videira, M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.06.010 · Cited by 35
Hesperetin inhibit EMT in TGF-β treated podocyte by regulation of mTOR pathway
Choi, D., Kim, C.-L., Kim, J. E., Mo, J., & Jeong, H.-S. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.087 · Cited by 35
Bautista, F., Paolettí, X., Rubino, J., Brard, C., Rezaï, K., Nebchi, S., André, N., Aerts, I., Carli, E. D., van Eijkelenburg, N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01152 · Cited by 35
Morscher, R. J., Brard, C., Berlanga, P., Marshall, L. V., André, N., Rubino, J., Aerts, I., Carli, É. D., Corradini, N., Nebchi, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.010 · Cited by 34
Lu, Z., Shi, X., Gong, F., Li, S., Wang, Y., Ren, Y., Zhang, M.-Y., Yu, B., Li, Y., Zhao, W. H., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.010 · Cited by 33
Self-citationAnnunziata, M. C., Parisi, M., Esposito, G., Fabbrocini, G., Ammendola, R., & Cattaneo, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113818 · Cited by 32
Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors
Gaur, S., Chen, L., Yang, L., Wu, X., Un, F., & Yen, Y. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.005 · Cited by 31
Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma
Choi, S. W., Lee, Y., Shin, K., Koo, H., Kim, D., Sa, J. K., Cho, H. J., Shin, H.-M., Lee, S. J., Kim, H., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03657-0 · Cited by 30
Gαq activation modulates autophagy by promoting mTORC1 signaling
Cabezudo, S., Sanz‐Flores, M., Caballero, Á., Tasset, I., Rebollo, E., Díaz, A., Aragay, A. M., Cuervo, A. M., Mayor, F., & Ribas, C. (2021) · Nature Communications · doi:10.1038/s41467-021-24811-4 · Cited by 30
Bian, Y., Xu, J., Zhao, W., Zhang, Z., Tu, L., Cao, H., & Zhang, Z. (2017) · Europe PMC (PubMed Central) · Cited by 25
Moura, A. C., Assad, D. X., dos Santos, J. A., de Toledo, I. P., Barra, G. B., CASTILHO, R. M., SQUARIZE, C. H., & Guerra, E. N. S. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103284 · Cited by 25
Wang, C., Feng, Y., Zhang, C., Cheng, D., Wu, R., Yang, Y., Sargsyan, D., Kumar, D., & Kong, A. T. (2019) · The FASEB Journal · doi:10.1096/fj.201901205rr · Cited by 24
Aurora-A Induces Chemoresistance Through Activation of the AKT/mTOR Pathway in Endometrial Cancer
Wu, J., Cheng, Z., Xu, X., Fu, J., Wang, K., Liu, T., Wu, C., Kong, X., Yang, Q., Yan, G., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00422 · Cited by 21
Lim, B., Potter, D. A., Salkeni, M. A., Silverman, P., Haddad, T. C., Forget, F., Awada, A. H., Canon, J.-L. R., Danso, M. A., Lortholary, A. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4131 · Cited by 19
Revisiting mTOR and Epithelial–Mesenchymal Transition
Herrerias, M. M., & Budinger, G. R. S. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0109ed · Cited by 14
How mTORC1 makes sense of nutrients
Luciani, A., & Stagi, M. (2020) · Kidney International · doi:10.1016/j.kint.2020.07.052 · Cited by 6
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
Tian, L.-Y., Smit, D. J., & Jücker, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032652 · Cited by 329
Helicobacter pylori and gastric cancer: mechanisms and new perspectives
Duan, Y., Xu, Y., Dou, Y., & Xu, D. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01654-2 · Cited by 300
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Q., Li, Z., Luo, T., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 264
Metadata
- Authors
- Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2022-03-24
- Volume
- 12
- Pages
- 819128-819128
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W4221041782
- Cited by
- 763
- References
- 118
- FWCI
- 45.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.